keyword
MENU ▼
Read by QxMD icon Read
search

dpp-4 inhibitor

keyword
https://www.readbyqxmd.com/read/28726205/dipeptidyl-peptidase-4-inhibitors-diprotin-a-and-sitagliptin-administered-on-weeks-2-3-of-postnatal-development-modulate-monoamine-metabolism-in-the-striatum-of-adult-rats
#1
N N Khlebnikova, E V Orshanskaya, V B Narkevich, V S Kudrin, N A Krupina
The levels of monoamines and their metabolites in brain structures of adult (3-month-old) rats with emotional and motivational disorders induced by inhibitors of dipeptidyl peptidase 4 (DPP-4; EC 3.4.14.5) diprotin A and sitagliptin on weeks 2-3 of postnatal development (postnatal days 5-18) were studied by HPLC with electrochemical detection. A significant decrease in the level of serotonin metabolite, 5-hydroxyindoleacetic acid, and a pronounced tendency towards reduced serotonin level were detected in the striatum of rats in both study groups...
July 18, 2017: Bulletin of Experimental Biology and Medicine
https://www.readbyqxmd.com/read/28725273/a-randomized-controlled-trial-comparing-the-effects-of-dapagliflozin-and-dpp-4-inhibitors-on-glucose-variability-and-metabolic-parameters-in-patients-with-type-2-diabetes-mellitus-on-insulin
#2
Hiroshi Nomoto, Hideaki Miyoshi, Hajime Sugawara, Kota Ono, Shingo Yanagiya, Mayuko Oita, Akinobu Nakamura, Tatsuya Atsumi
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose co-transporter 2 (SGLT2) inhibitors improve hyperglycemia, and the usefulness of co-administration of DPP-4 inhibitors and insulin therapy has been well established. However, it has been still uncertain whether combination therapy of SGLT2 inhibitors and insulin is superior to that of DPP-4 inhibitors and the latter. Therefore, we investigated the superiority of dapagliflozin on glucose fluctuation compared with DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2DM) on insulin using a continuous glucose monitoring (CGM) system...
2017: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/28715446/active-subfractions-of-abelmoschus-esculentus-substantially-prevent-free-fatty-acid-induced-%C3%AE-cell-apoptosis-via-inhibiting-dipeptidyl-peptidase-4
#3
Chien-Ning Huang, Chau-Jong Wang, Yi-Ju Lee, Chiung-Huei Peng
Lipotoxicity plays an important role in exacerbating type 2 diabetes mellitus (T2DM) and leads to apoptosis of β cells. Recently dipeptidyl peptidase-4 (DPP-4) inhibitors have emerged as a useful tool in the treatment of T2DM. DPP-4 degrades type 1 glucagon-like peptide (GLP-1), and GLP-1 receptor (GLP-1R) signaling has been shown to protect β cells by modulating AMPK/mTOR, PI3K, and Bax. The anti-hyperglycemic effect of Abelmoschus esculentus (AE) is well known, however its mucilage makes it difficult to further examine this effect...
2017: PloS One
https://www.readbyqxmd.com/read/28704854/switching-from-premixed-insulin-to-basal-insulin-analogue-for-type-2-diabetes-and-role-of-dipeptidyl-peptidase-4-inhibitors
#4
Fernando Gómez-Peralta, Cristina Abreu, Gustavo Mora-Navarro, Pilar López-Morandeira, Esteban Pérez-Gutierrez, Blanca Cordero-García, Miguel Brito-Sanfiel
Introduction This study aimed to confirm the usefulness of basal insulin analogue plus oral antidiabetic drugs (OADs) for type 2 diabetes (T2D) patients inadequately controlled with premixed insulin with/without OADs and assess the role of dipeptidyl peptidase-4 (DPP-4) inhibitors within this regimen in clinical practice. Methods Spanish retrospective observational study that included 186 T2D patients with glycosylated hemoglobin (HbA1c) >7% (53 mmol/mol) despite premixed insulin with/without OADs who had been switched to basal insulin analogue plus OADs...
July 13, 2017: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/28701284/cost-effectiveness-analysis-of-different-dipeptidyl-peptidase-4-inhibitor-drugs-for-treatment-of-type-2-diabetes-mellitus
#5
M S Cazarim, Estael Luzia Coelho da Cruz-Cazarim, A O Baldoni, Thais Bueno Enes Dos Santos, Paula Gonçalves de Souza, Ingrid de Almeida Silva, Roberta Niriam Reis Rodrigues, Alda Cristina Franco Correa Maia, Leonardo Régis Leira Pereira, Cristina Sanches
INTRODUCTION: Type 2 diabetes mellitus (T2DM) has burdened health systems in the world to the value of 500 billion dollars/year. Dipeptidyl peptidase 4 inhibitors (DPP-4 Inhibitors) have been strongly associated with spending on the treatment of T2DM by the courts in Brazil. The aim of this study was to estimate the most cost-effective DPP-4 Inhibitor for T2DM treatment. A pharmacoeconomic study of cost-effectiveness was performed in a medium-sized municipality in Minas Gerais state, Brazil...
July 3, 2017: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/28697774/the-impact-of-dpp-4-inhibitors-on-long-term-survival-among-diabetic-patients-after-first-acute-myocardial-infarction
#6
Mei-Tzu Wang, Sheng-Che Lin, Pei-Ling Tang, Wang-Ting Hung, Chin-Chang Cheng, Jin-Shiou Yang, Hong-Tai Chang, Chun-Peng Liu, Guang-Yuan Mar, Wei-Chun Huang
BACKGROUND: Previous studies regarding the cardioprotective effects of dipeptidyl peptidase 4 (DPP-4) inhibitors have not provided sufficient evidence of a relationship between DPP-4 inhibition and actual cardiovascular outcomes. This study aimed to evaluate the impact of DPP-4 inhibitors on the survival of diabetic patients after first acute myocardial infarction (AMI). METHODS: This was a nationwide, propensity score-matched, case-control study of 186,112 first AMI patients, 72,924 of whom had diabetes...
July 11, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28694704/health-care-provider-experience-with-canagliflozin-in-real-world-clinical-practice-favorability-treatment-patterns-and-patient-outcomes
#7
Susan C Bolge, Natalia M Flores, Shu Huang, Jennifer Cai
PURPOSE: This study describes how health care providers approach canagliflozin for the treatment of patients with type 2 diabetes mellitus (T2DM) in the real world. PATIENTS AND METHODS: An Internet-based questionnaire was completed by 101 endocrinologists, 101 primary care physicians, and 100 nurse practitioners/physician assistants (NP/PAs). Health care providers were required to have experience prescribing or managing patients using canagliflozin to be included in the study...
2017: International Journal of General Medicine
https://www.readbyqxmd.com/read/28692886/synthesis-and-characterization-of-oxidovanadium-complexes-as-enzyme-inhibitors-targeting-dipeptidyl-peptidase-iv
#8
Ming-Jin Xie, Ming-Rong Zhu, Chun-Mei Lu, Yi Jin, Li-Hui Gao, Ling Li, Jie Zhou, Fan-Fang Li, Qi Hua Zhao, Hong-Ke Liu, Peter J Sadler, Carlos Sanchez-Cano
Two oxidovanadium(IV) complexes carrying Schiff base ligands obtained from the condensation of 4,5-dichlorobenzene-1,2-diamine and salicylaldehyde derivatives were synthesised and characterised, including their X-ray crystallographic structures. They were evaluated as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes. These compounds were moderate inhibitors of DPP-IV, with IC50 values of ca. 40μM. In vivo tests showed that complexes 1 and 2 could lower significantly the level of glucose in the blood of alloxan-diabetic mice at doses of 22...
June 29, 2017: Journal of Inorganic Biochemistry
https://www.readbyqxmd.com/read/28685995/meta-analysis-and-critical-review-on-the-efficacy-and-safety-of-alpha-glucosidase-inhibitors-in-asian-and-non-asian-populations
#9
Xueying Gao, Xiaoling Cai, Wenjia Yang, Yifei Chen, Xueyao Han, Linong Ji
AIMS: To evaluate the efficacy and safety of alpha glucosidase inhibitors (AGI) in Asian and non-Asian type 2 diabetic patients. MATERIALS AND METHODS: Studies were identified through a literature search of MEDLINE, EMBASE, and other databases until December 2016. All statistical analyses were conducted in Review Manager statistical software by computing the weighted mean difference (WMD) or odds ratio (OR) and 95% confidence interval (CI). RESULTS: A total of 67 studies were included...
July 7, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/28676760/combined-oral-administration-of-gaba-and-dpp-4-inhibitor-prevents-beta-cell-damage-and-promotes-beta-cell-regeneration-in-mice
#10
Wenjuan Liu, Dong Ok Son, Harry K Lau, Yinghui Zhou, Gerald J Prud'homme, Tianru Jin, Qinghua Wang
γ-aminobutyric acid (GABA) or glucagon-like peptide-1 based drugs, such as sitagliptin (a dipeptidyl peptidase-4 inhibitor), were shown to induce beta cell regenerative effects in various diabetic mouse models. We propose that their combined administration can bring forth an additive therapeutic effect. We tested this hypothesis in a multiple low-dose streptozotocin (STZ)-induced beta cell injury mouse model (MDSD). Male C57BL/6J mice were assigned randomly into four groups: non-treatment diabetic control, GABA, sitagliptin, or GABA plus sitagliptin...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28671793/-gliptin-gliflozin-combination-for-treating-type-2-diabetes
#11
André J Scheen, Nicolas Paquot
Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require a combination of several pharmacological approaches to control hyperglycaemia. Combining a dipeptidyl peptidase-4 inhibitor (DPP-4i) and a sodium-glucose cotransporter type 2 inhibitor (SGT2i) appears to be an attractive approach because the two drugs exert different and potentially complementary glucose-lowering effects. Dual therapy (initial combination or stepwise approach) is more potent than either monotherapy in patients treated with diet and exercise or already treated with metformin...
August 24, 2016: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28665228/absorption-metabolism-and-excretion-of-14-c-omarigliptin-a-once-weekly-dpp-4-inhibitor-in-humans
#12
Shiyao Xu, Dan Tatosian, Ian Mcintosh, Maria Caceres, Catherine Matthews, Koppara Samuel, Diana Selverian, Sanjeev Kumar, Eunkyung Kauh
1. Omarigliptin (MARIZEV®) is a once-weekly DPP-4 inhibitor approved in Japan for the treatment of type 2 diabetes. The objective of this study was to investigate the absorption, metabolism and excretion of omarigliptin in humans. 2. Six healthy subjects received a single oral dose of 25 mg (2.1 µCi) [(14)C]omarigliptin. Blood, plasma, urine and fecal samples were collected at various intervals for up to 20 days post-dose. Radioactivity levels in excreta and plasma/blood samples were determined by accelerator mass spectrometry (AMS)...
June 30, 2017: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/28664354/impact-of-medicine-withdrawal-on-reporting-of-adverse-events-involving-therapeutic-alternatives-a-study-from-the-french-spontaneous-reporting-database
#13
Cécile Pageot, Julien Bezin, Andy Smith, Mickael Arnaud, Francesco Salvo, Françoise Haramburu, Bernard Bégaud, Antoine Pariente
INTRODUCTION: The consequences of the withdrawal of marketing authorisation of drugs have mostly been studied considering drug prescription patterns for the therapeutic alternatives of the withdrawn drugs. The potential concomitant changes in the reporting of adverse reactions concerning these alternatives have been studied less often. OBJECTIVE: The objective of this study was to analyse the changes in the reporting of adverse events (AEs) for therapeutic alternatives after the withdrawal of three medicines (dextropropoxyphene, pioglitazone and tetrazepam) from the market for safety reasons...
June 29, 2017: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/28661561/comparative-safety-of-pioglitazone-versus-clinically-meaningful-treatment-alternatives-on-the-risk-of-bladder-cancer-in-older-us-adults-with-type-2-diabetes
#14
Elizabeth M Garry, John B Buse, Jennifer L Lund, Virginia Pate, Til Stürmer
AIMS: Compare bladder cancer incidence between patients initiating pioglitazone and patients initiating dipeptidyl-peptidase-4 inhibitors [DPP-4 s] or sulfonylureas. METHODS: We identified Medicare beneficiaries aged >65 initiating pioglitazone (N = 38,700), DPP-4 s (N = 82,552), or sulfonylureas (N = 126,104) 2007-2014 after at least 6 months without prescriptions for these drug classes. Patients were followed from second prescription until bladder cancer outcome (2 claims within 60 days) using a 6-month induction/latency period, censoring for treatment change, death, or end of 2014...
June 29, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28656707/efficacy-and-safety-of-sodium-glucose-cotransporter-2-inhibitors-versus-dipeptidyl-peptidase-4-inhibitors-as-monotherapy-or-add-on-to-metformin-in-patients-with-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis
#15
Zhiying Wang, Jiahui Sun, Ruobing Han, Dongzhu Fan, Xinyi Dong, Zenghui Luan, Rongwu Xiang, Mingyi Zhao, Jingyu Yang
AIMS: To compare the efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP-4is) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) as monotherapy or add-on to metformin (Met) in patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: PubMed, Embase, and ClinicalTrials.gov were systematically searched for randomized controlled trials to assess the efficacy and safety of DPP-4is and SGLT-2is in patients with T2DM. Risk ratio (RR) and weighted mean difference (WMD) were used to evaluate the outcomes...
June 28, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28652790/sitagliptin-ameliorates-oxidative-stress-in-experimental-diabetic-nephropathy-by-diminishing-the-mir-200a-keap-1-nrf2-antioxidant-pathway
#16
Esther Civantos, Enrique Bosch, Elisa Ramirez, Olha Zhenyukh, Jesús Egido, Oscar Lorenzo, Sebastián Mas
BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in type 2 diabetes therapy, has demonstrated protective effects in diabetic chronic kidney disease, in part due to its pleiotropic actions. However, its potential direct effects on the kidney are still not completely defined. Here, by means of proteomics and miRNA profiling, we have further unveiled the role of sitagliptin in oxidative stress, as well as the underlying mechanisms. METHODS: Renal cortex samples from 9-month-old wild-type (Wistar), type II diabetic Goto-Kakizaki (GK) and sitagliptin-treated GK rats (GK+Sita) (10 mg kg(-1) per day) were subjected to quantitative miRNA transcriptomic array, immunohistochemistry and Western blot studies...
2017: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/28647512/effect-of-dipeptidyl-peptidase-4-inhibitors-on-circulating-tumor-necrosis-factor-%C3%AE-concentrations-a-systematic-review-and-meta-analysis-of-controlled-trials
#17
REVIEW
Stephen L Atkin, Niki Katsiki, Maciej Banach, Dimitri P Mikhailidis, Matteo Pirro, Amirhossein Sahebkar
OBJECTIVE: Dipeptidyl peptidase-4 (DPP-4) inhibitors improve glycemic control in patients with type 2 diabetes mellitus. There are also reports of an effect of these drugs in reducing inflammation through inhibition of tumor necrosis factor-α (TNF-α) that is an important mediator for several inflammatory processes. The present systematic review and meta-analysis were performed to evaluate the effect of DPP-4 inhibitors on circulating TNF-α levels in T2DM patients. METHODS: A systematic review and a meta-analysis were undertaken on all controlled trials of DPP-4 inhibitors that included measurement of TNF-α...
June 3, 2017: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/28646701/use-of-sglt2-inhibitors-for-diabetes-and-risk-of-infection-analysis-using-general-practice-records-from-the-nps-medicinewise-medicineinsight-program
#18
Svetla Gadzhanova, Nicole Pratt, Elizabet Roughead
AIMS: To explore the feasibility of MedicineInsight data to support risk management plan evaluation, focusing on sodium glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes. METHODS: A retrospective study using de-identified electronic general practitioner records. Patients who initiated SGLT2 inhibitor between 1 Jan 2012 to 1 Sep 2015 were compared to patients who initiated dipeptidyl peptidase 4 (DPP-4) inhibitors. The two cohorts were followed-up for six months...
June 15, 2017: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/28640433/glycemic-improvement-with-a-fixed-dose-combination-of-dpp-4-inhibitor%C3%A2-%C3%A2-metformin-in-patients-with-type-2-diabetes-gift-study
#19
Harpreet S Bajaj, Chenglin Ye, Esha Jain, Karri Venn, Eden Stein, Ronnie Aronson
This study investigates changes in A1C following a switch from dual therapy of metformin and DPP-4 inhibitor to a fixed-dose combination (FDC) of metformin + DPP-4 inhibitor following the introduction of the FDC in the provincial formulary. LMC Diabetes Registry was queried retrospectively for patients with type 2 diabetes, aged between 18-80 years with at least one A1C recorded prior and ≥3 months post-switch. 568 subjects with mean age 64 ± 12 years and mean A1C 7.7% ± 1.2% met study criteria...
June 22, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28640111/comparative-safety-for-cardiovascular-outcomes-of-dpp-4-inhibitors-versus-glimepiride-in-patients-with-type-2-diabetes-a-retrospective-cohort-study
#20
COMPARATIVE STUDY
Hyouk-Jun Chin, Jin Hyun Nam, Eui-Kyung Lee, Ju-Young Shin
Concerns about the cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors persist. This study sought to determine whether there is a differential risk of hospitalization for cardiovascular diseases (CVDs) between DPP-4 inhibitors and glimepiride.We conducted this retrospective cohort study by using the Korean National Health Insurance Service database from December 1, 2008, to December 31, 2013. The study subjects were new users of DPP-4 inhibitors or glimepiride for type 2 diabetes. Outcome was defined as hospitalization for CVDs, including angina pectoris, myocardial infarction, transient cerebral ischemic attack, heart failure, or cerebrovascular disease or any procedure involving coronary artery bypass grafting or percutaneous coronary intervention...
June 2017: Medicine (Baltimore)
keyword
keyword
69346
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"